Peptimmune Issues Second Close on Series D

Peptimmune, a Cambridge, Mass.-based biotechnology company, completed a second close on its Series D venture backing, worth $8.9 million. The round was led by New Enterprise Associates, MPM Capital, Hunt Ventures L.P., Boston Medical Investors and Silicon Valley Bank Capital, and its Chairman of the Board. Company Web site